Narlaprevir

Star0

DB14760InvestigationalSmall molecule

Narlaprevir: Overview.

Mechanism: Pharmacologically active on NS3 protease, Genome polyprotein, and Replicase polyprotein 1ab
Curator reviewed
Formula / weight: C₃₆H₆₁N₅O₇S · 707.97 g/mol (avg)
Code names: SCH-900518

Resolves to

Compound

UNII2857LA2O07CAS865466-24-6

Clinical / RWD

ATCJ05AP14

Structure

InChIKeyRICZEKWVNZFTNZ-IOBYQIKSSA-NSMILESCCCCC(NC(=O)C1[C@@H]2[C@H](CN1C(=O)C(NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1

Targets

Q91RS4NS3 proteaseB0B3C9NS3/4AP0DTD1rep

What you can answer from here — as of July 07, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 17 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Narlaprevir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account